AmerisourceBergen Corporation (NYSE:ABC) Files An 8-K Regulation FD Disclosure


AmerisourceBergen Corporation (NYSE:ABC) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

On June 19, 2017, AmerisourceBergen Corporation issued a news
release, a copy of which is attached hereto as Exhibit 99.1.
The information contained in this Current Report, including
Exhibit 99.1, shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in
such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description of Exhibit
News release issued by AmerisourceBergen Corporation on
June 19, 2017.

EX-99.1 2 amerisourcerebergennewsrel.htm EXHIBIT 99.1 Exhibit   Exhibit 99.1  AmerisourceBergen CorporationP.O. Box 959Valley Forge,…
To view the full exhibit click here
About AmerisourceBergen Corporation (NYSE:ABC)

AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company’s segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers. Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment’s operations provide drug distribution and related services. The Other segment consists of the operations of various segments, including the AmerisourceBergen Consulting Services (ABCS), the World Courier Group, Inc. and the MWI Veterinary Supply, Inc. ABSG operates distribution facilities that focus primarily on complex disease treatment regimens.

An ad to help with our costs